[go: up one dir, main page]

NO20084129L - Pyridin(3,4-B)Pyrazinoner - Google Patents

Pyridin(3,4-B)Pyrazinoner

Info

Publication number
NO20084129L
NO20084129L NO20084129A NO20084129A NO20084129L NO 20084129 L NO20084129 L NO 20084129L NO 20084129 A NO20084129 A NO 20084129A NO 20084129 A NO20084129 A NO 20084129A NO 20084129 L NO20084129 L NO 20084129L
Authority
NO
Norway
Prior art keywords
pyrazinoner
pyridine
compounds
disclosed
methods
Prior art date
Application number
NO20084129A
Other languages
English (en)
Inventor
Michael John Palmer
Andrew Simon Bell
David Louis Brown
David Graham Brown
Christopher Phillips
Michael Brent Tollefson
Robert O Hughes
Dafydd Rhys Owen
Yvette Marlene Fobian
John Nicholas Freskos
Steven Edward Heasley
Eric Jon Jacobsen
Todd Michael Maddux
Brent Virgil Mischke
John Major Molyneaux
Joseph Blair Moon
Jr Donald Joseph Rogier
John Keith Walker
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20084129L publication Critical patent/NO20084129L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Det beskrives forbindelser og farmasøytisk akseptable salter av forbindelsene, hvor forbindelsene har strukturen av Formel I: hvor R2, R6A, R6Bog R8 er som definert i beskrivelsen. Korresponderende farmasøytiske sammensetninger, fremgangsmåter for behandling, metoder for syntese, og mellomprodukter beskrives også.
NO20084129A 2006-04-21 2008-09-29 Pyridin(3,4-B)Pyrazinoner NO20084129L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79397106P 2006-04-21 2006-04-21
PCT/IB2007/001001 WO2007122466A1 (en) 2006-04-21 2007-04-10 Pyridine[3,4-b]pyrazinones

Publications (1)

Publication Number Publication Date
NO20084129L true NO20084129L (no) 2008-10-29

Family

ID=38431249

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084129A NO20084129L (no) 2006-04-21 2008-09-29 Pyridin(3,4-B)Pyrazinoner

Country Status (41)

Country Link
US (1) US7902195B2 (no)
EP (1) EP2013208B1 (no)
JP (1) JP4436892B2 (no)
KR (1) KR101061328B1 (no)
CN (1) CN101454320B (no)
AP (1) AP2408A (no)
AR (1) AR060525A1 (no)
AT (1) ATE513831T1 (no)
AU (1) AU2007242555B2 (no)
BR (1) BRPI0710658A2 (no)
CA (1) CA2649775C (no)
CR (1) CR10327A (no)
CU (1) CU23777B7 (no)
CY (1) CY1111739T1 (no)
DK (1) DK2013208T3 (no)
DO (1) DOP2007000080A (no)
EA (1) EA014919B1 (no)
EC (1) ECSP088803A (no)
ES (1) ES2366239T3 (no)
GT (1) GT200700035A (no)
HR (1) HRP20110539T1 (no)
IL (1) IL194591A (no)
MA (1) MA30352B1 (no)
ME (1) MEP23808A (no)
MX (1) MX2008012456A (no)
MY (1) MY148583A (no)
NL (1) NL2000583C2 (no)
NO (1) NO20084129L (no)
NZ (1) NZ571540A (no)
PA (1) PA8724201A1 (no)
PE (1) PE20080192A1 (no)
PL (1) PL2013208T3 (no)
RS (2) RS20080484A (no)
SI (1) SI2013208T1 (no)
SV (1) SV2008003074A (no)
TN (1) TNSN08408A1 (no)
TW (1) TWI337609B (no)
UA (1) UA92637C2 (no)
UY (1) UY30291A1 (no)
WO (1) WO2007122466A1 (no)
ZA (1) ZA200808283B (no)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20110539T1 (hr) 2006-04-21 2011-08-31 Pfizer Products Inc. PIRIDINO[3,4-b]PIRAZINONI
HUE025355T2 (en) * 2006-12-12 2016-02-29 Gilead Sciences Inc Composition for treating pulmonary hypertension
DK2247292T3 (en) 2008-03-05 2017-06-06 Merck Patent Gmbh PYRIDOPYRAZINO DERIVATIVES, AS INSULIN SECRETION STIMULATORS, PROCEDURES FOR OBTAINING THESE AND USE THEREOF IN THE TREATMENT OF DIABETES
WO2010041711A1 (ja) * 2008-10-09 2010-04-15 杏林製薬株式会社 イソキノリン誘導体及びそれらを有効成分とするpde阻害剤
MY177695A (en) * 2009-10-26 2020-09-23 Signal Pharm Llc Methods of synthesis and purification of heteroaryl compounds
KR20150002876A (ko) 2010-10-15 2015-01-07 길리애드 사이언시즈, 인코포레이티드 폐 고혈압 치료의 조성물 및 방법
WO2012131539A1 (en) 2011-03-31 2012-10-04 Pfizer Inc. Novel bicyclic pyridinones
WO2012172449A1 (en) 2011-06-13 2012-12-20 Pfizer Inc. Lactams as beta secretase inhibitors
EP2751116B1 (en) 2011-08-31 2016-10-12 Pfizer Inc Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds
ES2585262T3 (es) 2012-05-04 2016-10-04 Pfizer Inc Compuestos heterocíclicos de hexahidropiran[3,4-d][1,3]tiazin-2-amina sustituidos como inhibidores de PPA, BACE1 y BACE2
JP2015529239A (ja) 2012-09-20 2015-10-05 ファイザー・インク アルキル置換ヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
CA2893256A1 (en) 2012-12-11 2014-06-19 Pfizer Inc. Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
EP2935282A1 (en) 2012-12-19 2015-10-28 Pfizer Inc. CARBOCYCLIC- AND HETEROCYCLIC-SUBSTITUTED HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS
JP2016507551A (ja) 2013-02-13 2016-03-10 ファイザー・インク ヘテロアリール置換ヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
MD20150071A2 (ro) 2013-02-19 2016-02-29 Pfizer Inc. Compuşi azabenzimidazolici ca inhibitori ai PDE4 izoenzimelor pentru tratamentul tulburărilor SNC şi altor afecţiuni
WO2015049616A1 (en) 2013-10-04 2015-04-09 Pfizer Inc. Novel bicyclic pyridinones as gamma-secretase modulators
JO3466B1 (ar) * 2013-12-20 2020-07-05 Takeda Pharmaceuticals Co مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
AP2016009465A0 (en) 2014-04-01 2016-09-30 Pfizer Chromene and 1,1 a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators
KR20180078347A (ko) 2014-04-10 2018-07-09 화이자 인코포레이티드 2-아미노-6-메틸-4,4a,5,6-테트라히드로피라노[3,4-d][1,3]티아진-8a(8H)-일-1,3-티아졸-4-일 아미드
US10131669B2 (en) 2014-07-24 2018-11-20 Pfizer Inc. Pyrazolopyrimidine compounds
HUE044040T2 (hu) 2014-08-06 2019-09-30 Pfizer Imidazopiridazin vegyületek
EP3253755B1 (en) 2015-02-03 2020-08-26 Pfizer Inc Novel cyclopropabenzofuranyl pyridopyrazinediones
TN2017000485A1 (en) 2015-06-17 2019-04-12 Pfizer Tricyclic compounds and their use as phosphodiesterase inhibitors
EP3353182A1 (en) 2015-09-24 2018-08-01 Pfizer Inc Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors
JP2018531923A (ja) 2015-09-24 2018-11-01 ファイザー・インク N−[2−(2−アミノ−6,6−二置換−4,4a,5,6−テトラヒドロピラノ[3,4−d][1,3]チアジン−8a(8H)−イル)−1,3−チアゾール−4−イル]アミド
JP2018534251A (ja) 2015-09-24 2018-11-22 ファイザー・インク Bace阻害剤として有用なn−[2−(3−アミノ−2,5−ジメチル−1,1−ジオキシド−5,6−ジヒドロ−2h−1,2,4−チアジアジン−5−イル)−1,3−チアゾール−4−イル]アミド
AU2017223132B2 (en) 2016-02-23 2019-12-05 Pfizer Inc. 6,7-Dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds
HUE054857T2 (hu) 2016-07-01 2021-10-28 Pfizer 5,7-dihidro-pirrolo-piridinszármazékok neurológiai és neurodegeneratív betegségek kezelésére
US11198692B2 (en) 2017-06-22 2021-12-14 Pfizer Inc. Dihydro-pyrrolo-pyridine derivatives
MX2019015578A (es) * 2017-06-28 2020-07-28 Ptc Therapeutics Inc Metodos para tratar la enfermedad de huntington.
WO2019183636A1 (en) 2018-03-23 2019-09-26 Pfizer Inc. Piperazine azaspiro derivaves
US12144815B2 (en) 2021-02-23 2024-11-19 Hoth Therapeutics, Inc. Use of aprepitant for treating Alzheimer's disease
WO2024118524A1 (en) 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Azaindole compounds and their use as phosphodiesterase inhibitors
WO2025145091A1 (en) 2023-12-29 2025-07-03 Pfizer Inc. Crystalline forms of a muscarinic m4 receptor modulator and methods of treating diseases
WO2025160132A1 (en) * 2024-01-23 2025-07-31 Maplight Therapeutics, Inc. Gpr6 inverse agonists

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1361652A (fr) 1963-06-21 1964-05-22 Ciba Geigy Procédé de préparation de diazines, entre autres de la 2-méthyl-6-hydroxy-7-morpholino-ptéridine
JP2550456B2 (ja) 1990-11-06 1996-11-06 山之内製薬株式会社 縮合ピラジン誘導体
TW274550B (no) 1992-09-26 1996-04-21 Hoechst Ag
JP2000154139A (ja) 1998-09-16 2000-06-06 Kyowa Hakko Kogyo Co Ltd 縮環ピラジン誘導体
US6369056B1 (en) 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6465465B1 (en) * 2000-03-14 2002-10-15 Arzneimittelwerk Dresden Gmbh Process for the treatment of erectile dysfunction and product therefor
NZ527741A (en) * 2001-02-26 2005-02-25 Tanabe Seiyaku Co Pyridopyrimidine or naphthyridine derivative
WO2002076954A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
US20030114469A1 (en) * 2001-09-27 2003-06-19 Cohen David Saul Combinations
US7067658B2 (en) 2002-09-30 2006-06-27 Bristol-Myers Squibb Company Pyridino and pyrimidino pyrazinones
JP2007504283A (ja) 2003-05-20 2007-03-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア β−アミロイド斑に作用物質を結合させる方法
ATE461196T1 (de) 2003-06-26 2010-04-15 Merck Sharp & Dohme Benzodiazepin-cgrp-rezeptor-antagonisten
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
CA2593005A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Pharmaceutical compounds as activators of caspases and inducers of apoptosis and the use thereof
WO2006126082A2 (en) * 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
AU2006284403A1 (en) 2005-08-26 2007-03-01 Methylgene Inc. Benzodiazepine and benzopiperazine analog inhibitors of histone deacetylase
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
HRP20110539T1 (hr) 2006-04-21 2011-08-31 Pfizer Products Inc. PIRIDINO[3,4-b]PIRAZINONI

Also Published As

Publication number Publication date
RS20080484A (sr) 2009-07-15
CN101454320A (zh) 2009-06-10
MEP23808A (en) 2010-06-10
TNSN08408A1 (fr) 2010-04-14
MY148583A (en) 2013-04-30
NL2000583C2 (nl) 2007-12-14
UA92637C2 (en) 2010-11-25
GT200700035A (es) 2008-02-05
RS51885B (sr) 2012-02-29
TWI337609B (en) 2011-02-21
CA2649775C (en) 2011-05-31
CU20080194A7 (es) 2011-03-21
AR060525A1 (es) 2008-06-25
JP2009534368A (ja) 2009-09-24
CU23777B7 (es) 2012-02-15
NZ571540A (en) 2010-10-29
US7902195B2 (en) 2011-03-08
CA2649775A1 (en) 2007-11-01
TW200808794A (en) 2008-02-16
JP4436892B2 (ja) 2010-03-24
SI2013208T1 (sl) 2011-09-30
ECSP088803A (es) 2008-11-27
AP2408A (en) 2012-05-30
CN101454320B (zh) 2012-12-19
ZA200808283B (en) 2009-11-25
MX2008012456A (es) 2008-10-10
PA8724201A1 (es) 2009-08-26
WO2007122466A1 (en) 2007-11-01
KR101061328B1 (ko) 2011-08-31
NL2000583A1 (nl) 2007-10-23
AP2008004640A0 (en) 2008-10-31
ATE513831T1 (de) 2011-07-15
PL2013208T3 (pl) 2011-10-31
KR20080110930A (ko) 2008-12-19
BRPI0710658A2 (pt) 2011-08-16
DK2013208T3 (da) 2011-08-15
HRP20110539T1 (hr) 2011-08-31
EP2013208A1 (en) 2009-01-14
DOP2007000080A (es) 2007-11-15
PE20080192A1 (es) 2008-03-01
EP2013208B1 (en) 2011-06-22
CR10327A (es) 2008-10-21
CY1111739T1 (el) 2015-10-07
US20070249615A1 (en) 2007-10-25
AU2007242555A1 (en) 2007-11-01
HK1133875A1 (en) 2010-04-09
EA014919B1 (ru) 2011-04-29
SV2008003074A (es) 2010-01-12
MA30352B1 (fr) 2009-04-01
IL194591A (en) 2012-07-31
ES2366239T3 (es) 2011-10-18
EA200801998A1 (ru) 2009-04-28
AU2007242555B2 (en) 2010-12-16
UY30291A1 (es) 2007-11-30

Similar Documents

Publication Publication Date Title
NO20084129L (no) Pyridin(3,4-B)Pyrazinoner
NO20091893L (no) Nye 1,4-benzotiepin-1,1-dioksidderivater som er substituert med benzylgrupper, fremgangsmater for fremstilling av medisiner inneholdende forbindelsene og anvendelse derav.
WO2007135527A3 (en) Benzimidazolyl compounds
NO20074703L (no) Antibakterielle piperidinderivater
MX2012000414A (es) Derivados piridin-4-ilo.
NO20071617L (no) Indozolonderivater som 11B-HSD1-inhibitorer
NO20066055L (no) Pyridinderivater
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
NO20076695L (no) Nye MCHR1-antagonister og deres anvendelse for behandling av MCHR1-medierte tilstander og forstyrrelser
NO20072831L (no) Imidazo[1,2-A]Pyridinforbindelser, sammensetninger, anvendelser og fremgangsmater relatert dertil
NO20085068L (no) Fenylamino-benzoksazolsubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
NO20072371L (no) Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister
NO20070445L (no) Pyrimidinderivater.
NO20054852L (no) GFAT inhibitorer
WO2008077557A8 (en) 8-ethinylxanthine derivatives as selective a2a receptor antagonists
NO20091590L (no) Heterocykliske amidforbindelser anvendbare som kinaseinhibitorer
NO20091741L (no) Pyrazolinforbindelser som mineralkortikoidreceptorantagonister
NO20071658L (no) Alkil-pyridiner som 11-beta-inhibitorer for diabetes
WO2006126082A3 (en) Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
IN2012DN03182A (no)
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
NO20073551L (no) Nikotinacetylkolinreseptorligander
UA99787C2 (en) Lactams as beta secretase inhibitors
MX2009013501A (es) Compuestos piperidinicos y sus usos.
NO20080033L (no) Kinolinderivater som NK3-antagonister

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application